Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment.

Kruger DF, LaRue S, Estepa P.

Diabetes Metab Syndr Obes. 2015 Jan 16;8:49-56. doi: 10.2147/DMSO.S71923. eCollection 2015. Review.

2.

Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat).

Spolding B, Connor T, Wittmer C, Abreu LL, Kaspi A, Ziemann M, Kaur G, Cooper A, Morrison S, Lee S, Sinclair A, Gibert Y, Trevaskis JL, Roth JD, El-Osta A, Standish R, Walder K.

PLoS One. 2014 Mar 20;9(3):e92656. doi: 10.1371/journal.pone.0092656. eCollection 2014.

3.

Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.

Levy OE, Jodka CM, Ren SS, Mamedova L, Sharma A, Samant M, D'Souza LJ, Soares CJ, Yuskin DR, Jin LJ, Parkes DG, Tatarkiewicz K, Ghosh SS.

PLoS One. 2014 Feb 4;9(2):e87704. doi: 10.1371/journal.pone.0087704. eCollection 2014.

4.

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.

Tatarkiewicz K, Polizzi C, Villescaz C, D'Souza LJ, Wang Y, Janssen S, Parkes DG.

Diabetes Obes Metab. 2014 Apr;16(4):376-80. doi: 10.1111/dom.12237. Epub 2013 Dec 9.

5.

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.

Trevaskis JL, Mack CM, Sun C, Soares CJ, D'Souza LJ, Levy OE, Lewis DY, Jodka CM, Tatarkiewicz K, Gedulin B, Gupta S, Wittmer C, Hanley M, Forood B, Parkes DG, Ghosh SS.

PLoS One. 2013 Oct 22;8(10):e78154. doi: 10.1371/journal.pone.0078154. eCollection 2013.

6.

A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Tatarkiewicz K, Hargrove DM, Jodka CM, Gedulin BR, Smith PA, Hoyt JA, Lwin A, Collins L, Mamedova L, Levy OE, D'Souza L, Janssen S, Srivastava V, Ghosh SS, Parkes DG.

Diabetes Obes Metab. 2014 Jan;16(1):75-85. doi: 10.1111/dom.12181. Epub 2013 Aug 19.

7.
8.

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.

Macconell L, Pencek R, Li Y, Maggs D, Porter L.

Diabetes Metab Syndr Obes. 2013;6:31-41. doi: 10.2147/DMSO.S35801. Epub 2013 Jan 21.

9.

Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes.

Malloy J, Gurney K, Shan K, Yan P, Chen S.

Diabetes Metab Syndr Obes. 2012;5:419-24. doi: 10.2147/DMSO.S34241. Epub 2012 Dec 17.

10.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

11.

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.

Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R.

Vasc Health Risk Manag. 2012;8:621-9. doi: 10.2147/VHRM.S37969. Epub 2012 Nov 12.

12.

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.

Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D.

Diabetes Obes Metab. 2013 May;15(5):417-26. doi: 10.1111/dom.12040. Epub 2012 Dec 7.

13.

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.

Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S.

Int J Clin Pract. 2012 Nov;66(11):1021-32. doi: 10.1111/j.1742-1241.2012.03006.x. Epub 2012 Aug 24.

14.

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.

Meloni AR, DeYoung MB, Lowe C, Parkes DG.

Diabetes Obes Metab. 2013 Jan;15(1):15-27. doi: 10.1111/j.1463-1326.2012.01663.x. Epub 2012 Aug 1. Review.

15.

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.

Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.

Vasc Health Risk Manag. 2012;8:255-64. doi: 10.2147/VHRM.S28744. Epub 2012 Apr 23.

16.

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.

Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, Noel RA, Braun DK, Bloomgren GL.

Diabet Med. 2012 Nov;29(11):1412-8. doi: 10.1111/j.1464-5491.2012.03652.x.

17.
18.

Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.

Endocr Pract. 2011 Nov-Dec;17(6):922-32. doi: 10.4158/EP11229.OR.

19.

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P.

Diabetes Technol Ther. 2011 Nov;13(11):1145-54. doi: 10.1089/dia.2011.0050. Epub 2011 Jul 13. Review.

20.

Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.

Stonehouse A, Walsh B, Cuddihy R.

Diabetes Technol Ther. 2011 Oct;13(10):1063-9. doi: 10.1089/dia.2011.0076. Epub 2011 Jul 6. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk